Fig. 4

Effects of MCC950 on endometriosis lesions and ovaries of a murine endometriosis model. (A) Experimental design of the role of MCC950 in a murine ovarian endometriosis model. (B) Hematoxylin and eosin staining of lesions; Scale bar: 500 μm (left) and 50 μm (right). (C) Macroscopic view of lesions (left) and volumes of lesions per ovary were assessed (right). Data are presented as mean ± SEM; PBS-treated (n = 8 mice, 16 ovaries) and MCC950-treated (n = 7 mice, 14 ovaries); scale bar: 2 mm. (D and E) Histological analysis of murine endometriosis lesions treated with vehicle and MCC950, by staining for Ki67 (D) and IL-1β (E). Representative immunohistochemical localization (left, scale bar: 50 μm), and quantitative analysis of positive epithelial area ratio of the endometriotic cyst wall or eutopic endometrium (right). (F) Representative 4-HNE immunohistochemical results of ovarian follicles in primordial, primary, secondary, pre-antral, and antral stages; scale bar: 20 μm. (G–K) Quantitative analysis of each follicular stage of the ovary. Data are shown as mean ± SEM of at least eight follicles from four mice. Statistical significances were calculated using Student’s t-test (C, D, and G–K) and one-way ANOVA followed by Dunnett’s multiple comparison test (E). *P < 0.05; **P < 0.01; n.s., not significant; IP intraperitoneal, OE ovarian endometriosis, EM eutopic endometrium, 4-HNE 4-hydroxynonenal